Emerging PSA-based tests to improve screening

Urologic Clinics of North America

Volumn 41, Issue 2, 2014, Pages 267-276

  Bryant, Richard J ^a   Lilja, Hans ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Detection; Kallikreins; Prostate cancer; PSA; Screening

Indexed keywords

FREE INACTIVE PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN 3; KALLIKREIN RELATED PEPTIDASE 2; PRO PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TOTAL PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER SCREENING; DIGITAL RECTAL EXAMINATION; FREEZE THAWING; GLEASON SCORE; HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; UNNECESSARY PROCEDURE;

DETECTION; KALLIKREINS; PROSTATE CANCER; PSA; SCREENING;

DIAGNOSTIC ERRORS; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MODELS, STATISTICAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84898484195     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2014.01.003     Document Type: Review

References (131)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
2. Hugosson J., Carlsson S., Aus G., et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010, 11(8):725-732.
3. Schroder F.H., Hugosson J., Roobol M.J., et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366(11):981-990.
4. Vickers A.J., Ulmert D., Sjoberg D.D., et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013, 346:f2023.
5. Vickers A.J., Lilja H. Predicting prostate cancer many years before diagnosis: how and why?. World J Urol 2012, 30(2):131-135.
6. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360(13):1320-1328.
7. Welch H.G., Albertsen P.C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009, 101(19):1325-1329.
8. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998, 279(19):1542-1547.
9. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004, 350(22):2239-2246.
10. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008, 8(4):268-278.
11. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005, 294(1):66-70.
12. Ulmert D., Serio A.M., O'Brien M.F., et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008, 26(6):835-841.
13. Drazer M.W., Huo D., Schonberg M.A., et al. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 2011, 29(13):1736-1743.
14. Ross L.E., Taylor Y.J., Richardson L.C., et al. Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006. J Natl Med Assoc 2009, 101(4):316-324.
15. Sirovich B.E., Schwartz L.M., Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA 2003, 289(11):1414-1420.
16. Loeb S., Carter H.B., Berndt S.I., et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011, 186(5):1830-1834.
17. Summaries for patients. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157(2):1-44.
18. Ablin R.J., Soanes W.A., Bronson P., et al. Precipitating antigens of the normal human prostate. J Reprod Fertil 1970, 22(3):573-574.
19. Chan D.W., Bruzek D.J., Oesterling J.E., et al. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem 1987, 33(10):1916-1920.
20. Kuriyama M., Wang M.C., Lee C.I., et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 1981, 41(10):3874-3876.
21. Kuriyama M., Wang M.C., Papsidero L.D., et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980, 40(12):4658-4662.
22. Oesterling J.E., Chan D.W., Epstein J.I., et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988, 139(4):766-772.
23. Papsidero L.D., Wang M.C., Valenzuela L.A., et al. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980, 40(7):2428-2432.
24. Seamonds B., Yang N., Anderson K., et al. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Urology 1986, 28(6):472-479.
25. Sensabaugh G.F. Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci 1978, 23(1):106-115.
26. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317(15):909-916.
27. Wang M.C., Papsidero L.D., Kuriyama M., et al. Prostate antigen: a new potential marker for prostatic cancer. Prostate 1981, 2(1):89-96.
28. Wang M.C., Valenzuela L.A., Murphy G.P., et al. Purification of a human prostate specific antigen. Invest Urol 1979, 17(2):159-163.
29. Polascik T.J., Oesterling J.E., Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 1999, 162(2):293-306.
30. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597.
31. Pound C.R., Walsh P.C., Epstein J.I., et al. Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World J Urol 1997, 15(6):373-377.
32. Stephenson R.A., Stanford J.L. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol 1997, 15(6):331-335.
33. Henttu P., Liao S.S., Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 1992, 130(2):766-772.
34. Young C.Y., Montgomery B.T., Andrews P.E., et al. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991, 51(14):3748-3752.
35. Diamandis E.P., Yousef G.M. Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Expert Rev Mol Diagn 2001, 1(2):182-190.
36. Diamandis E.P., Yousef G.M., Luo L.Y., et al. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000, 11(2):54-60.
37. Levesque M., Hu H., D'Costa M., et al. Prostate-specific antigen expression by various tumors. J Clin Lab Anal 1995, 9(2):123-128.
38. Christensson A., Laurell C.B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990, 194(3):755-763.
39. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985, 76(5):1899-1903.
40. Lilja H., Laurell C.B. Liquefaction of coagulated human semen. Scand J Clin Lab Invest 1984, 44(5):447-452.
41. Lilja H., Oldbring J., Rannevik G., et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987, 80(2):281-285.
42. McGee R.S., Herr J.C. Human seminal vesicle-specific antigen is a substrate for prostate-specific antigen (or P-30). Biol Reprod 1988, 39(2):499-510.
43. Christensson A., Bjork T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993, 150(1):100-105.
44. Christensson A., Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994, 220(1):45-53.
45. Lilja H. Prostate-specific antigen: molecular forms and the human kallikrein gene family. Br J Urol 1997, 79(Suppl 1):44-48.
46. Lilja H., Christensson A., Dahlen U., et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991, 37(9):1618-1625.
47. McCormack R.T., Rittenhouse H.G., Finlay J.A., et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995, 45(5):729-744.
48. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991, 51(1):222-226.
49. Brawer M.K. Prostate-specific antigen: current status. CA Cancer J Clin 1999, 49(5):264-281.
50. Partin A.W., Brawer M.K., Bartsch G., et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003, 170(5):1787-1791.
51. Lee R., Localio A.R., Armstrong K., et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006, 67(4):762-768.
52. Partin A.W., Brawer M.K., Subong E.N., et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998, 1(4):197-203.
53. Roddam A.W., Duffy M.J., Hamdy F.C., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005, 48(3):386-399. [discussion: 98-9].
54. Stephan C., Jung K., Diamandis E.P., et al. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002, 59(1):2-8.
55. Veltri R.W., Miller M.C. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations. Urology 1999, 53(4):736-745.
56. Vessella R.L., Lange P.H., Partin A.W., et al. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. Urology 2000, 55(6):909-914.
57. Kumar A., Mikolajczyk S.D., Goel A.S., et al. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997, 57(15):3111-3114.
58. Kumar A., Mikolajczyk S.D., Hill T.M., et al. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. Prostate 2000, 44(3):248-254.
59. Mikolajczyk S.D., Grauer L.S., Millar L.S., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997, 50(5):710-714.
60. Mikolajczyk S.D., Marker K.M., Millar L.S., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001, 61(18):6958-6963.
61. Mikolajczyk S.D., Marks L.S., Partin A.W., et al. Free prostate-specific antigen in serum is becoming more complex. Urology 2002, 59(6):797-802.
62. Peter J., Unverzagt C., Krogh T.N., et al. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001, 61(3):957-962.
63. Zhang W.M., Leinonen J., Kalkkinen N., et al. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995, 41(11):1567-1573.
64. Bangma C.H., Wildhagen M.F., Yurdakul G., et al. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 2004, 93(6):720-724.
65. Lein M., Semjonow A., Graefen M., et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 2005, 174(6):2150-2153.
66. Martin B.J., Finlay J.A., Sterling K., et al. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA). Prostate Cancer Prostatic Dis 2004, 7(2):132-137.
67. Mikolajczyk S.D., Catalona W.J., Evans C.L., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004, 50(6):1017-1025.
68. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000, 60(3):756-759.
69. Mikolajczyk S.D., Rittenhouse H.G. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease. Rinsho Byori 2004, 52(3):223-230.
70. Mikolajczyk S.D., Song Y., Wong J.R., et al. Are multiple markers the future of prostate cancer diagnostics?. Clin Biochem 2004, 37(7):519-528.
71. Nurmikko P., Pettersson K., Piironen T., et al. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 2001, 47(8):1415-1423.
72. Sokoll L.J., Chan D.W., Mikolajczyk S.D., et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology 2003, 61(2):274-276.
73. Steuber T., Nurmikko P., Haese A., et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 2002, 168(5):1917-1922.
74. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003, 170(6 Pt 1):2181-2185.
75. Catalona W.J., Partin A.W., Sanda M.G., et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011, 185(5):1650-1655.
76. de Vries S.H., Raaijmakers R., Blijenberg B.G., et al. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology 2005, 65(5):926-930.
77. Filella X., Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013, 51(4):729-739.
78. Guazzoni G., Lazzeri M., Nava L., et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012, 61(3):455-466.
79. Guazzoni G., Nava L., Lazzeri M., et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011, 60(2):214-222.
80. Houlgatte A., Vincendeau S., Desfemmes F., et al. Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients. Prog Urol 2011, 22(5):279-283.
81. Isharwal S., Makarov D.V., Sokoll L.J., et al. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011, 77(3)(763):e1-e6.
82. Jansen F.H., van Schaik R.H., Kurstjens J., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57(6):921-927.
83. Le B.V., Griffin C.R., Loeb S., et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010, 183(4):1355-1359.
84. Makarov D.V., Isharwal S., Sokoll L.J., et al. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009, 15(23):7316-7321.
85. Sokoll L.J., Sanda M.G., Feng Z., et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010, 19(5):1193-1200.
86. Sokoll L.J., Wang Y., Feng Z., et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008, 180(2):539-543. [discussion: 43].
87. Stephan C., Kahrs A.M., Cammann H., et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009, 69(2):198-207.
88. Nurmikko P., Vaisanen V., Piironen T., et al. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000, 46(10):1610-1618.
89. Pinzani P., Lind K., Malentacchi F., et al. Prostate-specific antigen mRNA and protein levels in laser microdissected cells of human prostate measured by real-time reverse transcriptase-quantitative polymerase chain reaction and immuno-quantitative polymerase chain reaction. Hum Pathol 2008, 39(10):1474-1482.
90. Armitage T.G., Cooper E.H., Newling D.W., et al. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br J Urol 1988, 62(6):584-589.
91. Dalton D.L. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989, 33(6):465.
92. Ercole C.J., Lange P.H., Mathisen M., et al. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987, 138(5):1181-1184.
93. Nadler R.B., Humphrey P.A., Smith D.S., et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995, 154(2 Pt 1):407-413.
94. Partin A.W., Carter H.B., Chan D.W., et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990, 143(4):747-752.
95. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324(17):1156-1161.
96. Carter H.B. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older. Urology 2000, 55(6):796-799.
97. Catalona W.J., Ramos C.G., Carvalhal G.F., et al. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000, 55(6):791-795.
98. Catalona W.J., Southwick P.C., Slawin K.M., et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000, 56(2):255-260.
99. Becker C., Piironen T., Kiviniemi J., et al. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 2000, 46(2):198-206.
100. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997, 49(6):857-862.
101. Finlay J.A., Evans C.L., Day J.R., et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 1998, 51(5):804-809.
102. Klee G.G., Goodmanson M.K., Jacobsen S.J., et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem 1999, 45(6 Pt 1):800-806.
103. Lovgren J., Valtonen-Andre C., Marsal K., et al. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 1999, 20(3):348-355.
104. Martin B.J., Cheli C.D., Sterling K., et al. Prostate specific antigen isoforms and human glandular kallikrein 2-which offers the best screening performance in a predominantly black population?. J Urol 2006, 175(1):104-107.
105. Nam R.K., Diamandis E.P., Toi A., et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 2000, 18(5):1036-1042.
106. Piironen T., Pettersson K., Suonpaa M., et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996, 48(6A Suppl):81-87.
107. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., et al. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998, 35(4):275-368.
108. Stephan C., Jung K., Lein M., et al. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000, 9(11):1133-1147.
109. Young C.Y., Andrews P.E., Montgomery B.T., et al. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 1992, 31(3):818-824.
110. Yousef G.M., Kyriakopoulou L.G., Scorilas A., et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res 2001, 61(21):7811-7818.
111. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999, 53(5):939-944.
112. Kwiatkowski M.K., Recker F., Piironen T., et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 1998, 52(3):360-365.
113. Tremblay R.R., Deperthes D., Tetu B., et al. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol 1997, 150(2):455-459.
114. Nakamura T., Mitsui S., Okui A., et al. Molecular cloning and expression of a variant form of hippostasin/KLK11 in prostate. Prostate 2003, 54(4):299-305.
115. Nakamura T., Stephan C., Scorilas A., et al. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology 2003, 61(5):1042-1046.
116. Obiezu C.V., Soosaipillai A., Jung K., et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 2002, 48(8):1232-1240.
117. Parekh D.J., Ankerst D.P., Baillargeon J., et al. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(10):1966-1972.
118. Sardana G., Marshall J., Diamandis E.P. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem 2007, 53(3):429-437.
119. Xi Z., Klokk T.I., Korkmaz K., et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004, 64(7):2365-2370.
120. Yousef G.M., Stephan C., Scorilas A., et al. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 2003, 56(4):287-292.
121. Vickers A.J., Cronin A.M., Aus G., et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008, 6:19.
122. Ulmert D., Becker C., Nilsson J.A., et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 2006, 52(2):235-239.
123. Benchikh A., Savage C., Cronin A., et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010, 10:635.
124. Gupta A., Roobol M.J., Savage C.J., et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer 2010, 103(5):708-714.
125. Vickers A., Cronin A., Roobol M., et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010, 28(15):2493-2498.
126. Vickers A.J., Cronin A.M., Aus G., et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 2010, 116(11):2612-2620.
127. Vickers A.J., Cronin A.M., Roobol M.J., et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010, 16(12):3232-3239.
128. Vickers A.J., Gupta A., Savage C.J., et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011, 20(2):255-261.
129. European Association of Urology. Prostate cancer. Full guidelines. 2012 [cited 7th May 2013]. Available at: Accessed May 7, 2013. http://www.uroweb.org/guidelines/online-guidelines/.
130. Nichol M.B., Wu J., An J.J., et al. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection. Prostate Cancer Prostatic Dis 2011, 14(3):253-261.
131. Murphy D. The Melbourne Consensus Statement on Prostate Cancer Testing. 2013 [cited 24th November 2013]. Available at: Accessed November 24, 2013. http://www.bjuinternational.com/bjui-blog/the-melbourne-consensus-statement-on-prostate-cancer-testing/.